Global Medtech Companies Seeking Ways To Fortify Competitive Advantage In China
This article was originally published in PharmAsia News
Executive Summary
Ranked only behind the U.S., China’s medtech market is set for a boom as more physicians are trained to perform common medical procedures that are still low-penetrating. Multinational manufacturers will have to fend off strong domestic firms.
You may also be interested in...
What Lies Beneath China's Steep Price Cuts For New Drugs
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Asia Executives On The Move: BMS, Pfizer, Takeda, RDPAC
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.
Who's In And Who's Out In China's Largest Reimbursed Drug List Revamp?
Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: